Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diflucan Generics Launch Following Expiration Of Pfizer Exclusivity

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approves numerous ANDAs for tablet, oral suspension and injectable forms of the antifungal upon expiration of Diflucan's six-month pediatric extension. Pfizer is marketing its own generic through its Greenstone subsidiary.
Advertisement

Related Content

Pfizer To Spring Forward With Eraxis Launch
Pfizer To Spring Forward With Eraxis Launch
Pfizer Vfend Approved For Candidemia
Pfizer Vfend Approved For Candidemia
Pfizer Expects To File 12 "Major" NDAs By The End Of 2006
Pfizer Expects To File 12 "Major" NDAs By The End Of 2006
Pfizer’s Glucotrol XL Generic Not Cutting Into Andrx’ Market Share
Ranbaxy Diflucan Generic Delayed Until July, Court Affirms
Ranbaxy Diflucan Generic Launch Delayed Until July Under Court Ruling
Ranbaxy Diflucan Generic Launch Delayed Until July Under Court Ruling

Topics

Advertisement
UsernamePublicRestriction

Register

PS060170

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel